Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Novo valuation surpasses Tesla on experimental obesity drug data—Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline—Biden proposes strengthening Medicare’s drug pricing power--http://bit.ly/w28kSd #novonordisk #obesity #clinicaltrials #biogen #alzheimers #biden #medicare #drugpricing #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi—J&J could face class action for allegedly mismanaging employee health plan — Gilead will not buy Tizona after paying $300M for the right to do so--http://bit.ly/w28kSd #eisai #biogen #alzheimers #jnj #employeebenefits #legal #gileadsciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

An expected news from Alzheimer therapies, https://www.alzforum.org/news/community-news/adieu-aduhelm-biogen-stops-marketing-antibody

A bit nostalgic, though, because I was one of the few whose cognition improved (relatively, i.e. compared to the control-group) during the years I got the antibody 10 mg / kg, enough for Biogen to apply for license.

It was a marvellous box-seat to observe pharmaceutical research with all it's intricacies, and live neurological expertise within an arm's reach was invaluable.

Here is the history of aducanumab, rest in pieces, https://www.alzforum.org/therapeutics/aduhelm

Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal - Enlarge / The exterior of the headquarters of biotechnology company Bio... - https://arstechnica.com/?p=2000435 #clinicaltrial #aducanumab #alzheimers #science #aduhelm #health #biogen #fda

Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news http://bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

quote :
厚生勞動省（相當於衛生福利部）專家小組8月21日審核通過 #日本 #衛采製藥 （ #Eisai ）與 #美國 藥廠 #百健（ #Biogen ）合作開發的 #阿茲海默症 新藥 #Lecanemab （又稱為 #Leqembi ）。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

https://www.cna.com.tw/news/aopl/202309250285.aspx

Alzheimer's Drug Leqembi to be available in some areas in a few months https://politicaliq.com/2023/08/07/alzheimers-drug-leqembi-to-be-available-in-some-areas-in-a-few-months/ #Alzheimer #alzheimersdisease #Leqembi #FDA #Esai #Biogen #Medicare #politicaliq #news #politics

Sage's new #antidepressant is more like an antibiotic than an SSRI: it's taken for 14 days, then re-dosed as needed. But its long-term effectiveness is debatable.

Turns out, it's so rapid-acting that some psychiatrists don't even care. But will the #FDA?

My preview ahead of the FDA decision:
www.statnews.com/2023/07/31/sage-zuranolone-antidepressant-fda/

Four senior #FDA leaders forged close ties with #Biogen ahead of #Aduhelm's approval. Now they've all left FDA. Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers
https://endpts.com/four-senior-fda-leaders-forged-close-ties-with-biogen-ahead-of-aduhelms-approval-now-theyve-all-left-fda/ #revolvingdoor #quidproquo

FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)

The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda

Ars Technica: FDA approves new Alzheimer’s treatment despite risks, unclear benefits https://arstechnica.com/?p=1908494 #Tech #arstechnica #IT #Technology #Cognitivedecline #Alzheimer's #treatment #antibody #approval #Science #Biogen #eisai #fda

Congressional inquiry into 'highly atypical' #FDA-#Biogen ties ends with damning report, no repercussions, a slap on the wrist for both and a roadmap for how other companies may leverage behind-the-scenes interactions with FDA leaders to their advantage https://bit.ly/3Ckusy1

#Aduhelm never should have been approved by the #FDA. This was a blatant case of #RegulatoryCapture. Of course #Biogen's credibility was damaged; they DESERVED for their credibility to be damaged.
#alzheimers #MediFedi #MedMastodon
(Free link, no paywall)
https://www.washingtonpost.com/science/2022/12/29/alzheimers-fda-biogen-aduhelm/?pwapi_token=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWJpZCI6IjI5Nzk3NjciLCJyZWFzb24iOiJnaWZ0IiwibmJmIjoxNjcyMzQzMzcxLCJpc3MiOiJzdWJzY3JpcHRpb25zIiwiZXhwIjoxNjczNTUyOTcxLCJpYXQiOjE2NzIzNDMzNzEsImp0aSI6ImY0MmNhN2ZiLTA0NTQtNGYzMC1iNTg4LTYwMzMwN2Y4N2JkZiIsInVybCI6Imh0dHBzOi8vd3d3Lndhc2hpbmd0b25wb3N0LmNvbS9zY2llbmNlLzIwMjIvMTIvMjkvYWx6aGVpbWVycy1mZGEtYmlvZ2VuLWFkdWhlbG0vIn0.J6PDbNGZIotZYPlvsEcggNUmZSXrq3BK7YB9tZYJyNM&itid=gfta

Congressional probe
Finds Biogen to blame for high
Price on Alzheimer's Drug

#alzheimers #biogen #fda #haiku #poetry

https://www.nytimes.com/2022/12/29/health/alzheimers-drug-aduhelm-biogen.html